{"id":28837,"date":"2026-08-21T15:52:57","date_gmt":"2026-08-21T07:52:57","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=28837"},"modified":"2026-08-27T12:23:22","modified_gmt":"2026-08-27T04:23:22","slug":"snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/","title":{"rendered":"Snapshot Week 35\/2026<br> A novel approach to produce TBE vaccine antigens"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Zhang et al. <br>A replication-defective tick-borne encephalitis virus generated by NS1 trans-complementation confers robust protective efficacy. <em>Virol Sin.<\/em> Published online July 30, 2026. doi:10.1016\/j.virs.2026.07.010<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">All licensed TBE vaccines are so far based on inactivated whole-virus particles.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An NS1 trans-complementation platform has been applied to TBE vaccine design, generating replication-defective TBE virus particles with a deletion in the gene encoding the nonstructural protein 1 (NS1). In this system, viral replication is supported in trans by a helper cell line expressing NS1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A TBE virus cDNA clone has been established with a large in-frame deletion (amino acids 4-298) of NS1 (TBEV-\u0394NS1). The deleted NS1 function is provided in trans by a BHK cell line stably expressing heterologous NS1 from the Omsk hemorrhagic fever virus (BHKNS1). The heterologous NS1 trans-complementation platform has been validated as reliable and highly efficient. The BHKNS1 cell line can rescue the replication defect of TBEV-\u0394NS1. TBEV-\u0394NS1 stably maintains the NS1 deletion during serial passaging, without recombination or reversion to a replication-competent wild-type virus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While ICR mice infected with wild-type virus became ill and died, no clinical manifestations or evidence of virulence were observed when mice were inoculated with TBEV-\u0394NS1. Mice inoculated with a single dose of TBEV-\u0394NS1 developed neutralizing antibodies, mounted a robust T-cell response, and were protected against a lethal challenge with wild-type virus (100% protection was observed at the higher dose of TBEV-\u0394NS1).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In summary, this replication-defective virus shows a promising preclinical safety and efficacy profile as a potential TBE vaccine candidate and warrants further development.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Zhang et al. A replication-defective tick-borne encephalitis virus generated by NS1 trans-complementation confers robust protective efficacy. Virol Sin. Published online July 30, 2026. doi:10.1016\/j.virs.2026.07.010 All licensed TBE vaccines are so far based on inactivated whole-virus particles. An NS1 trans-complementation platform has been applied to TBE vaccine design, generating replication-defective TBE virus particles with a deletion in the gene encoding the nonstructural protein 1 (NS1). In this system, viral replication is supported in trans by a helper cell line expressing NS1. A TBE virus cDNA clone has been established with a large in-frame deletion (amino acids 4-298) of NS1 (TBEV-\u0394NS1). The deleted NS1 function is provided in trans by a BHK cell line stably expressing heterologous NS1 from the Omsk hemorrhagic fever virus (BHKNS1). The heterologous NS1 trans-complementation platform has been validated as reliable and highly efficient. The BHKNS1 cell line can rescue the replication defect of TBEV-\u0394NS1. TBEV-\u0394NS1 stably maintains the NS1 deletion during serial passaging, without recombination or reversion to a replication-competent wild-type virus. While ICR mice infected with wild-type virus became ill and died, no clinical manifestations or evidence of virulence were observed when mice were inoculated with TBEV-\u0394NS1. Mice inoculated with a single dose of TBEV-\u0394NS1 developed neutralizing antibodies, mounted a robust T-cell response, and were protected against a lethal challenge with wild-type virus (100% protection was observed at the higher dose of TBEV-\u0394NS1). In summary, this replication-defective virus shows a promising preclinical safety and efficacy profile as a potential TBE vaccine candidate and warrants further development.<\/p>\n","protected":false},"author":94681,"featured_media":20968,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18,1324],"tags":[1047,1487,1488,249],"coauthors":[1108],"class_list":["post-28837","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","category-snapshot-2026","tag-nonstructural-protein-1","tag-replication-defective-tbe-virus","tag-trans-complementation","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Zhang et al. A replication-defective tick-borne encephalitis virus generated by NS1 trans-complementation confers robust protective efficacy. Virol Sin. Published online July 30, 2026. doi:10.1016\/j.virs.2026.07.010 All licensed TBE vaccines are so far based on inactivated whole-virus particles. An NS1 trans-complementation platform has been applied to TBE vaccine design, generating replication-defective TBE virus particles with a deletion in the gene encoding the nonstructural protein 1 (NS1). In this system, viral replication is supported in trans by a helper cell line expressing NS1. A TBE virus cDNA clone has been established with a large in-frame deletion (amino acids 4-298) of NS1 (TBEV-\u0394NS1). The deleted NS1 function is provided in trans by a BHK cell line stably expressing heterologous NS1 from the Omsk hemorrhagic fever virus (BHKNS1). The heterologous NS1 trans-complementation platform has been validated as reliable and highly efficient. The BHKNS1 cell line can rescue the replication defect of TBEV-\u0394NS1. TBEV-\u0394NS1 stably maintains the NS1 deletion during serial passaging, without recombination or reversion to a replication-competent wild-type virus. While ICR mice infected with wild-type virus became ill and died, no clinical manifestations or evidence of virulence were observed when mice were inoculated with TBEV-\u0394NS1. Mice inoculated with a single dose of TBEV-\u0394NS1 developed neutralizing antibodies, mounted a robust T-cell response, and were protected against a lethal challenge with wild-type virus (100% protection was observed at the higher dose of TBEV-\u0394NS1). In summary, this replication-defective virus shows a promising preclinical safety and efficacy profile as a potential TBE vaccine candidate and warrants further development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T07:52:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T04:23:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"logesan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"logesan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/\"},\"author\":{\"name\":\"logesan\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/eea00490409f8d848a28485d0f68fac3\"},\"headline\":\"Snapshot Week 35\\\/2026 A novel approach to produce TBE vaccine antigens\",\"datePublished\":\"2026-08-21T07:52:57+00:00\",\"dateModified\":\"2026-08-27T04:23:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/\"},\"wordCount\":264,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"keywords\":[\"Nonstructural protein 1\",\"Replication-defective TBE virus\",\"trans-complementation\",\"vaccine\"],\"articleSection\":[\"Snapshot\",\"Snapshot 2026\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/\",\"name\":\"Snapshot Week 35\\\/2026 A novel approach to produce TBE vaccine antigens - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2026-08-21T07:52:57+00:00\",\"dateModified\":\"2026-08-27T04:23:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot Week 35\\\/2026 A novel approach to produce TBE vaccine antigens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/eea00490409f8d848a28485d0f68fac3\",\"name\":\"logesan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g23fd037fb0950eb6606e07f441b58289\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g\",\"caption\":\"logesan\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/logesan\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens - TBE Book","og_description":"Zhang et al. A replication-defective tick-borne encephalitis virus generated by NS1 trans-complementation confers robust protective efficacy. Virol Sin. Published online July 30, 2026. doi:10.1016\/j.virs.2026.07.010 All licensed TBE vaccines are so far based on inactivated whole-virus particles. An NS1 trans-complementation platform has been applied to TBE vaccine design, generating replication-defective TBE virus particles with a deletion in the gene encoding the nonstructural protein 1 (NS1). In this system, viral replication is supported in trans by a helper cell line expressing NS1. A TBE virus cDNA clone has been established with a large in-frame deletion (amino acids 4-298) of NS1 (TBEV-\u0394NS1). The deleted NS1 function is provided in trans by a BHK cell line stably expressing heterologous NS1 from the Omsk hemorrhagic fever virus (BHKNS1). The heterologous NS1 trans-complementation platform has been validated as reliable and highly efficient. The BHKNS1 cell line can rescue the replication defect of TBEV-\u0394NS1. TBEV-\u0394NS1 stably maintains the NS1 deletion during serial passaging, without recombination or reversion to a replication-competent wild-type virus. While ICR mice infected with wild-type virus became ill and died, no clinical manifestations or evidence of virulence were observed when mice were inoculated with TBEV-\u0394NS1. Mice inoculated with a single dose of TBEV-\u0394NS1 developed neutralizing antibodies, mounted a robust T-cell response, and were protected against a lethal challenge with wild-type virus (100% protection was observed at the higher dose of TBEV-\u0394NS1). In summary, this replication-defective virus shows a promising preclinical safety and efficacy profile as a potential TBE vaccine candidate and warrants further development.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/","og_site_name":"TBE Book","article_published_time":"2026-08-21T07:52:57+00:00","article_modified_time":"2026-08-27T04:23:22+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"logesan","twitter_card":"summary_large_image","twitter_misc":{"Written by":"logesan","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/"},"author":{"name":"logesan","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/eea00490409f8d848a28485d0f68fac3"},"headline":"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens","datePublished":"2026-08-21T07:52:57+00:00","dateModified":"2026-08-27T04:23:22+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/"},"wordCount":264,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","keywords":["Nonstructural protein 1","Replication-defective TBE virus","trans-complementation","vaccine"],"articleSection":["Snapshot","Snapshot 2026"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/","name":"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","datePublished":"2026-08-21T07:52:57+00:00","dateModified":"2026-08-27T04:23:22+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-35-2026-a-novel-approach-to-produce-tbe-vaccine-antigens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot Week 35\/2026 A novel approach to produce TBE vaccine antigens"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/eea00490409f8d848a28485d0f68fac3","name":"logesan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g23fd037fb0950eb6606e07f441b58289","url":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3844852ce7cea119df4cb0d88d8862bd170a41490c4f4b8c784a3ff5d5bed353?s=96&d=mm&r=g","caption":"logesan"},"url":"https:\/\/tbenews.com\/tbe\/author\/logesan\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/94681"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=28837"}],"version-history":[{"count":4,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28837\/revisions"}],"predecessor-version":[{"id":28849,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/28837\/revisions\/28849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/20968"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=28837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=28837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=28837"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=28837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}